VanEck Pharmaceutical ETF
PPH
54 hedge funds and large institutions have $79M invested in VanEck Pharmaceutical ETF in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 7 closing their positions.
62% more capital invested
Capital invested by funds: $48.9M → $79M (+$30.2M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 53 → 54 (+1)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$11.9M |
| 2 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
+$7.18M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$2.81M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.35M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
Montag & Associates
Atlanta,
Georgia
|
-$1.5M |
| 2 |
VF
Virtu Financial
New York
|
-$1.5M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.12M |
| 4 |
BCM
Barometer Capital Management
Toronto,
Ontario, Canada
|
-$618K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$379K |
PPH Hedge Fund Activity: Q2 2014 in Review
54 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2014, worth a combined $79M — up 62% from $48.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PPH positions and 7 closed out — a net gain of 1 holder — while 17 added to existing stakes and 18 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Montag & Associates, cutting an estimated $1.5M.
- 54 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2014, up from 53 in Q1 2014.
- Funds reported $79M of VanEck Pharmaceutical ETF stock for Q2 2014, up 62% quarter-over-quarter.
- 8 funds opened new VanEck Pharmaceutical ETF positions in Q2 2014 and 7 closed out, a net change of +1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2014 was Goldman Sachs, an estimated $11.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2014 was Montag & Associates, an estimated $1.5M sold.
Based on aggregated 13F filings for Q2 2014.